Skip to main content

Advertisement

Log in

The ineligible patient: how to treat patients not included in clinical studies

  • Topic Paper
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

Purpose

Targeted therapies are currently the standard of care for metastatic renal cell carcinoma (mRCC). Five VEGF pathway inhibitors (sorafenib, sunitinib, bevacizumab in combination with interferon-alpha, pazopanib, and axitinib) and two mTOR inhibitors (everolimus and temsirolimus) are now FDA approved for mRCC based on results from phase III randomized clinical trials (RCTs). However, several subgroups of patients are excluded from enrollment due to strict eligibility criteria. The toxicity and efficacy of targeted therapies in these populations are unknown.

Methods

PubMed was searched for citations of the pivotal phase III RCTs leading to FDA approval. These publications were cross-referenced with their associated entries on www.ClinicalTrials.gov, and both were abstracted for eligibility criteria for patient enrollment. Based on this data, PubMed was searched for both prospective and retrospective studies evaluating toxicity and efficacy of targeted therapies for mRCC in these ineligible patient subgroups.

Results

We reviewed published toxicity and efficacy data in several ineligible patient subgroups, including patients with non-clear cell renal cell carcinoma, poor performance status, poor renal function, CNS metastases, significant cardiac comorbidities, and prior systemic therapy.

Conclusions

Targeted therapies appear to be safe in most ineligible patient populations, including patients with poor renal function. However, patients with preexisting cardiac comorbidities are at greater risk of developing cardiac toxicity on sunitinib. Targeted therapies appear to have some efficacy in maintaining stable disease in these subgroups, but are limited to rare partial responses. Prospective cohort studies are needed to accurately assess the safety and efficacy of targeted therapies in ineligible patient subgroups.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Schlesinger-Raab A, Treiber U, Zaak D, Hölzel D, Engel J (2008) Metastatic renal cell carcinoma: results of a population-based study with 25 years follow-up. Eur J Cancer 44(16):2485–2495

    Article  PubMed  Google Scholar 

  2. Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG (2010) CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ 340:c869

    Article  PubMed Central  PubMed  Google Scholar 

  3. Schulz K, Grimes D (2002) Sample size slippages in randomised trials: exclusions and the lost and wayward. Lancet 359:781–785

    Article  PubMed  Google Scholar 

  4. Braunholtz DA, Edwards SJ, Lilford RJ (2001) Are randomized clinical trials good for us (in the short term)? Evidence for a “trial effect”. J Clin Epidemiol 54(3):217–224

    Article  CAS  PubMed  Google Scholar 

  5. Peppercorn JM, Weeks JC, Cook EF, Joffe S (2004) Comparison of outcomes in cancer patients treated within and outside clinical trials: conceptual framework and structured review. Lancet 363(9405):263–270

    Article  PubMed  Google Scholar 

  6. Vist GE, Bryant D, Somerville L, Birminghem T, Oxman AD (2008) Outcomes of patients who participate in randomized controlled trials compared to similar patients receiving similar interventions who do not participate. Cochrane Database Syst Rev (3):MR000009. doi:10.1002/14651858.MR000009.pub4

  7. Hudes G, Carducci M, Tomczak P et al (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356(22):2271–2281

    Article  CAS  PubMed  Google Scholar 

  8. Therasse P (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92(3):205–216

    Article  CAS  PubMed  Google Scholar 

  9. Escudier B, Bellmunt J, Négrier S, Bajetta E, Melichar B, Bracarda S, Ravaud A, Golding S, Jethwa S, Sneller V (2010) Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 28(13):2144–2150

    Article  CAS  PubMed  Google Scholar 

  10. Rini BI, Halabi S, Rosenberg JE et al (2008) Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 26(33):5422–5428

    Article  CAS  PubMed  Google Scholar 

  11. Escudier B, Eisen T, Stadler WM et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356(2):125–134

    Article  CAS  PubMed  Google Scholar 

  12. Rini BI, Escudier B, Tomczak P et al (2011) Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378(9807):1931–1939

    Article  CAS  PubMed  Google Scholar 

  13. Motzer R, Bander N, Nanus D (1996) Renal-cell carcinoma. N Engl J Med 335(12):865–875

    Article  CAS  PubMed  Google Scholar 

  14. Lopez-Beltran A, Scarpelli M, Montironi R, Kirkali Z (2006) 2004 WHO classification of the renal tumors of the adults. Eur Urol 49(5):798–805

    Article  PubMed  Google Scholar 

  15. Deng F-M, Melamed J (2012) Histologic variants of renal cell carcinoma: does tumor type influence outcome? Urol Clin N Am 39(2):119–132

    Article  Google Scholar 

  16. Dutcher JP, De Souza P, McDermott D, Figlin Ra, Berkenblit A, Thiele A, Krygowski M, Strahs A, Feingold J, Hudes G (2009) Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med Oncol 26(2):202–209

    Article  CAS  PubMed  Google Scholar 

  17. Gore ME, Szczylik C, Porta C et al (2009) Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol 10(8):757–763

    Article  CAS  PubMed  Google Scholar 

  18. Stadler WM, Figlin RA, McDermott DF et al (2010) Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer 116(5):1272–1280

    Article  CAS  PubMed  Google Scholar 

  19. Choueiri TK, Plantade A, Elson P, Negrier S, Ravaud A, Oudard S, Zhou M, Rini BI, Bukowski RM, Escudier B (2008) Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol 26(1):127–131

    Article  CAS  PubMed  Google Scholar 

  20. Tannir NM, Plimack E, Ng C, et al (2012) A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma. Eur Urol. doi: 10.1016/j.eururo.2012.06.043

  21. Motzer R, Mazumdar M (1999) Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17(8):2530–2540

    CAS  PubMed  Google Scholar 

  22. Motzer RJ, Bacik J, Schwartz LH, Reuter V, Russo P, Marion S, Mazumdar M (2004) Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22(3):454–463

    Article  PubMed  Google Scholar 

  23. Choueiri TK, Garcia JA, Elson P, Khasawneh M, Usman S, Golshayan AR, Baz RC, Wood L, Rini BI, Bukowski RM (2007) Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer 110(3):543–550

    Article  CAS  PubMed  Google Scholar 

  24. Beck J, Procopio G, Bajetta E et al (2011) Final results of the European advanced renal cell carcinoma sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings. Ann Oncol 22(8):1812–1823

    Article  CAS  PubMed  Google Scholar 

  25. Gupta S, Parsa V, Heilbrun L, Smith D, Dickow B, Heath E, Vaishampayan U (2009) Safety and efficacy analysis of sunitinib (S), bevacizumab (B), and M-Tor inhibitors in metastatic renal cell cancer (mRCC) patients with renal insufficiency (RI). J Clin Oncol 27(15 s):suppl; abstr 5108

    Google Scholar 

  26. Josephs D, Hutson T (2011) Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis. BJU Int 108(8):1279–1283

    Article  CAS  PubMed  Google Scholar 

  27. Khosravan R, Toh M, Garrett M, La Fargue J, Ni G, Marbury TC, Swan SK, Lunde NM, Bello CL (2010) Pharmacokinetics and safety of sunitinib malate in subjects with impaired renal function. J Clin Pharmacol 50(4):472–481

    Article  CAS  PubMed  Google Scholar 

  28. Pfizer (2011) Sutent: highlights of prescribing information. http://labeling.pfizer.com/ShowLabeling.aspx?id=607. Accessed 11 Sep 2012

  29. Macfarlane R, Heng DYC, Xie W, Knox JJ, McDermott DF, Rini BI, Kollmannsberger C, Choueiri TK (2012) The impact of kidney function on the outcome of metastatic renal cell carcinoma patients treated with vascular endothelial growth factor-targeted therapy. Cancer 118(2):365–370

    Article  CAS  PubMed  Google Scholar 

  30. Saitoh H (1981) Distant metastasis of renal adenocarcinoma. Cancer 48(6):1487–1491

    Article  CAS  PubMed  Google Scholar 

  31. Wronski M, Maor MH, Davis BJ, Sawaya R, Levin VA (1997) External radiation of brain metastases from renal carcinoma: A retrospective study of 119 patients from the M. D. Anderson Cancer Center. Int J Radiat Oncol Biol Phys 37(4):753–759

  32. Nieder C (1999) Stereotactic radiosurgery for brain metastasis from renal cell carcinoma. Cancer 85(1):251–253

    Article  CAS  PubMed  Google Scholar 

  33. Culine S, Bekradda M, Kramar A, Rey A, Escudier B, Droz JP (1998) Prognostic factors for survival in patients with brain metastases from renal cell carcinoma. Cancer 83(12):2548–2553

    Article  CAS  PubMed  Google Scholar 

  34. Verma J, Jonasch E, Allen P, Tannir N, Mahajan A (2011) Impact of tyrosine kinase inhibitors on the incidence of brain metastasis in metastatic renal cell carcinoma. Cancer 117(21):4958–4965

    Article  CAS  PubMed  Google Scholar 

  35. Gore ME, Hariharan S, Porta C et al (2011) Sunitinib in metastatic renal cell carcinoma patients with brain metastases. Cancer 117(3):501–509

    Article  CAS  PubMed  Google Scholar 

  36. Telli ML, Witteles RM, Fisher GA, Srinivas S (2008) Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Ann Oncol 19(9):1613–1618

    Article  CAS  PubMed  Google Scholar 

  37. Di Lorenzo G, Autorino R, Bruni G et al (2009) Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis. Ann Oncol 20(9):1535–1542

    Article  PubMed  Google Scholar 

  38. Richards CJ, Je Y, Schutz FAB, Heng DYC, Dallabrida SM, Moslehi JJ, Choueiri TK (2011) Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib. J Clin Oncol 29(25):3450–3456

    Article  CAS  PubMed  Google Scholar 

  39. Greineder CF, Kohnstamm S, Ky B (2011) Heart failure associated with sunitinib: lessons learned from animal models. Curr Hypertens Rep 13(6):436–441

    Article  CAS  PubMed  Google Scholar 

  40. Gupta R, Maitland ML (2011) Sunitinib, hypertension, and heart failure: a model for kinase inhibitor-mediated cardiotoxicity. Curr Hypertens Rep 13(6):430–435

    Article  CAS  PubMed  Google Scholar 

  41. Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356(2):115–124

    Article  CAS  PubMed  Google Scholar 

  42. Escudier B, Pluzanska A, Koralewski P et al (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370(9605):2103–2111

    Article  PubMed  Google Scholar 

  43. Motzer RJ, Escudier B, Oudard S et al (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372(9637):449–456

    Article  CAS  PubMed  Google Scholar 

  44. Motzer RJ, Escudier B, Oudard S et al (2010) Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 116(18):4256–4265

    Article  CAS  PubMed  Google Scholar 

  45. (2012) National comprehensive cancer network guidelines for kidney cancer. http://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf. Accessed 19 Sep 2012

  46. Calvo E, Escudier B, Motzer RJ et al (2012) Everolimus in metastatic renal cell carcinoma: subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study. Eur J Cancer 48(3):333–339

    Article  CAS  PubMed  Google Scholar 

  47. Calvo E, Ravaud A, Bellmunt J (2012) What is the optimal therapy for patients with metastatic renal cell carcinoma who progress on an initial VEGFr-TKI? Cancer Treat Rev. doi: 10.1016/j.ctrv.2012.06.010

  48. Heng DY, Choueiri TK, Lee J-L et al (2012) A multicentered population-based analysis of outcomes of patients with metastatic renal cell carcinoma (mRCC) who do not meet eligibility criteria for clinical trials. J Clin Oncol 30(Suppl 5):abstr 353

  49. Rini BI, Halabi S, Rosenberg JE et al (2010) Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 28(13):2137–2143

    Google Scholar 

  50. Sternberg CN, Davis ID, Mardiak J et al (2010) Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28(6):1061–1068

    Google Scholar 

  51. Escudier B, Eisen T, Stadler WM et al (2009) Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 27(20):3312–3318

    Google Scholar 

Download references

Acknowledgments

This work received no specific grant from any funding agency in the public, commercial, or nonprofit sectors.

Conflict of interest

B. R. declares research funding and consulting fees for Pfizer, GSK, and AVEO.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Frances J. Mao.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mao, F.J., Rini, B.I. The ineligible patient: how to treat patients not included in clinical studies. World J Urol 32, 9–18 (2014). https://doi.org/10.1007/s00345-013-1042-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-013-1042-2

Keywords

Navigation